Norgine announces Swissmedic approval of PEDMARQSI® for the prevention of cisplatin induced hearing loss in children

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Norgine

More Like This

PR Newswire associated0

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

ACOUSIA THERAPEUTICS REACHES 50% PATIENT ENROLLMENT MILESTONE IN PHASE 2 PROHEAR STUDY

ACOUSIA ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE 2 PROHEAR STUDY EVALUATING ACOU085 (INN: BIMOKALNER) FOR THE PREVENTION OF CISPLATIN-INDUCED OTOTOXICITY

Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial

PR Newswire associated0

Norgine strengthens rare disease portfolio with acquisition of Theravia

Acousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease

Investors in the current financing round with AudioCure Management. From left to right: Philipp Zöller (CEO InfectoPharm), Prof Hans Rommelspacher (founder AudioCure), Dr Reimar Schlingensiepen (CEO AudioCure), Dr Ingeborg Hochmair (CEO MED-EL) and Dr Christian Kannemeier (Senior Investment Manager HTGF). Copyright: AudioCure.

InfectoPharm Invests in AudioCure to Advance Innovative Hearing Loss Therapy

PR Newswire associated0

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy